Verge Genomics’ Post

Anyone can develop GenAI apps these days, but developing industry changing - and arguably life changing - applications of GenAI is something BCG is uniquely positioned to do. Check out our new partnership with Merck to accelerate and enable drug development. #BCG #BCGX #innovation

Sharing data from Dealroom.co showing the GenAI Health landscape with 2024 deal sizes spanning from $15mil - 100m in size. Not seeing the larger deals (yet), but Q2/3 tends to be the most active period for bigger investments. We will be tracking progress monthly via our #AIAccelerator ---> https://lnkd.in/egnuFPiD Snapshot of the top deals in drug discovery AI: 💊 DeepCure $200m valuation and working on biotechnology to drive faster drug discovery - April 2024 💊 Hippocratic AI $500m valuation, working on first-safety focused LLM for healthcare - March 2024 💊 Curve Therapeutics $320m valuation, working on redefining drug discover for efficiency - Feb 2024 💊 Moonwalk Biosciences $274m valuation, focused on precise epigenetic solutions, mapping cellular states at genome level - Jan 2024 #dayonestrategy #genai #drugdiscovery

It’s been a worthwhile refresher and masterclass on Small Molecule Drug Discovery and Development by Africa’s pioneer global health, drug discovery and development organization, #Holistic Drug Discovery and Development Centre (H3D), University of Cape Town in collaboration with University of Cape Town. The highlight of this exhaustive curriculum for me is the global appeal for the responsible application of AI/ML and novel computational tools to bolster and refine the drug development value chain, from screening & hit ID to Phase IV studies. If ever AI/ML was relevant in transformative research and therapeutics, ‘tis now! #drugs #healthandsafety #artificialintelligence #deeplearning

Time is everything in drug discovery. We’ve slashed the time to discover and optimise pM affinity TCRs by more than half, breaking the barriers holding back the field. https://lnkd.in/evZFYksJ Our lead programme, ETC-101, is the world’s first AI-designed bispecific T cell engager. We have currently achieved single digit picomolar affinity - a million-fold higher affinity than the native receptor - with no known cross-reactivity detected. We’ve advanced ETC-101 to this stage in just 11 months using our generative-AI powered EMLy™ discovery engine, compared with 2+ years for conventional TCR discovery and engineering pipelines. This was achieved while simultaneously developing the platform, so future programmes should be even faster. Get in touch with our team if you’re interested in partnering with us to accelerate your TCR drug development pipeline: hello@etcembly.com #AI #generativeAI #Biotech #Immunotherapy #Tcells #DrugDevelopment

Throughout this month, we've had the honor of showcasing an array of innovative ventures, and now, as #NationalBlackBusinessMonth draws to a close, we want to highlight two more Black-owned businesses in the biotech industry. ✯ 1910 Genetics, founded by Jen Nwankwo, Ph.D. 1910 Genetics is a biotechnology company that integrates AI, computation, and biological automation to accelerate the design of small molecule and protein therapeutics. Its mission is to decrease the duration and expenses associated with drug development, all the while enhancing the success rate of delivering innovative medicines to patients in need. ✯ IndyGeneUS AI, founded by Yusuf Henriques and Bradford Wilson, PhD IndyGeneUS AI provides a decentralized, blockchain-secured platform for patients to confidentially store and analyze their genetic data and ultimately improve health outcomes. Their platform enables AI-powered understanding of disease, diagnostic biomarkers, and potential treatment targets. https://lnkd.in/ghmzYsUM

What does 2024 hold for biopharma? Eleanor Malone of Scrip Citeline Commercial features industry vanguards, including our Co-Founder and CTO Gevorg Grigoryan. Gevorg elucidates the pivotal role of #AI in revolutionizing biopharma, underscoring our leadership in driving these innovations.    In the article, Gevorg predicts that “soon we will see new drugs entering the clinic that have been completely computer-generated. Those medicines will transform the entire value chain from lab, to clinic, to regulatory approval, to the patient’s bedside. #MachineLearning has brought us to the brink of this revolution – we anticipate seeing the first clinical proofs of concept in 2024.”    Read more insights on the transformative technologies shaping the future of biopharma: https://lnkd.in/dWeM2Bcy    #ProteinEngineering I #GenerativeAI 

Hats off to Insilico Medicine, Alex Zhavoronkov, Feng Ren, 4B Technologies, Ltd for completing phase 2 patient enrollment for the fully AI-developed ALS drug. By target identification with PandaOmics, and further drug development, this partnership gave hope to tackling the currently untreatable disease in less than 2 years since the project started. This highlights the power of #AI drug development, and it's crucial role in minimizing the burden of disease. Kudos!

November 10th was World Science Day for Peace and Development, an annual event which highlights the important role of science in society and the need to engage the wider public in debates on emerging scientific issues. the theme for 2023 is "Building Trust in Science" In it's role as a leading science & technology company, MilliporeSigma contributes in many ways to help build trust in science. One example is Artificial Intelligence for Accelerating Drug Discovery. Our AI platform AIDDISON™ is revolutionizing drug development by rapidly identifying new drug candidates. This means more efficient disease treatment, quicker access to life-saving medications for patients, and a reduction in healthcare costs https://lnkd.in/g4S-REVK #drugdiscovery #drugdevelopment #ai #artificialintelligence #artificialgeneralintelligence #agi #medicinalchemistry

J.P. Morgan Week 2024 Highlights Over 8,000 global participants gathered in San Francisco for J.P. Morgan's 42nd Healthcare Conference, unveiling game-changing trends: Medable, Inc's new intelligent automation slashes clinical trial timelines by 50%, revolutionizing eCOA deployments and accelerating study startups. Top-10 pharma giants are already reaping the benefits. NVIDIA's $1 trillion valuation meets Amgen in a bid to transform drug discovery. The BioNeMo platform and AI system Freyja aim to reshape AI models, while Isomorphic Labs, backed by Alphabet Inc., pioneers drug discovery with Novartis and Eli Lilly and Company. Dr. Peter Marks unveils FDA's initiatives for advancing gene therapies in 2024. Streamlining platforms, accelerated approvals, regulatory harmony, and support for smaller companies through the START pilot program are on the agenda. Union Square buzzes with optimism, signaling a lasting shift in biotech attitudes. EY's Firepower report reveals a robust M&A capacity of $1.37 trillion for 2024, marking the second-highest figure in a decade. #JPMorganWeek #JPM2024 Reference: https://lnkd.in/d_sGuhfD Image Credit: Michael Weber/Courtesy of Westin St. Francis

Setting the Stage for 2024: Our Roadmap for Innovation As we step into 2024, CCRM Nordic is buzzing with anticipation. Our journey this year builds on the solid foundation we've established, propelling us towards new frontiers in regenerative medicine. Here’s what we’re setting out to achieve: 🔬 Laboratory and Office establishment: We’re hitting the ground running with the establishment of our process development laboratory and interim offices. Backed by a team with over 100 years of combined experience in cell and gene therapy, this pivotal step will ensure that we can provide state-of-the-art service offerings to ATMP developers. 🌱 Growth and Expertise: 2024 is all about building competence across the value chain and shaping our service offering. From research to delivery, we're strengthening our team to support the translation of innovative therapies from the lab to the patients who need them. 🏗️ GMP Facility Planning: The blueprint for our GMP facility is taking shape. We're finalizing layouts and plans to ensure our operations meet the highest standards for e.g. manufacturing and quality control. Apart from all of this, we're excited to unveil our new website, attend conferences, host events, and of course tell you more about exactly what we plan to do here at CCRM Nordic. While some of our goals are under wraps, these milestones hint at the transformative journey from establishing cutting-edge platforms to expanding our business support prowess. Join us as we document our journey throughout the year. #CCRMNordic #ATMP #CellAndGeneTherapy #Biotech #GoCo